TM editors' note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.

From Canada to Germany, the legal cannabis market continues to be one of the most attractive investment opportunities.

Over the last year, we have seen Canadian medical marijuana producers laser focus on international opportunities, most notably Germany following the medical cannabis law.

With over 80 million adults in Germany and with health insurance coverage for cannabis, the medical market could prove to be larger than that in Canada and we expect exports to become a more significant contributor to company sales in the coming quarters.

6 Cannabis Producers Focused on International Markets

Although the international cannabis markets are significant, only a few licensed producers that have the capital and ability to execute on these opportunities.

The legalization trend throughout the world has created significant opportunities for companies levered to the growth of this industry and we have highlighted six companies that are leading this charge. 

1. Last month, Canopy Growth Corp. (WEED.TO) (TWMJF) launched a strategic partnership in the Jamaican cannabis market as part of its ongoing international expansion. The Canadian firm is by far the largest and most diverse licensed medical marijuana producer and has a greater breadth of multi-site management than any other cannabis firm in the world. Canopy Growth is levered to the cannabis markets in Germany, Australia, Spain, Chile, Spain, and Denmark. We are favorable on Canopy Growth’s outlook and view it as one of the best long-term cannabis investment opportunities.
2. Aurora Cannabis Inc. (ACB.TO) (ACBFF) has been making waves in the global marijuana industry and is an industry leader. From Australia to Germany, this Canadian licensed producer has significantly increased its market share and is levered to new legal cannabis markets across the globe. Aurora Cannabis has a balance sheet that is flush with cash, we expect to see the company further expand its reach through additional acquisitions and investments over the next few months.
3. By now, most cannabis investors know that Aphria (APH.TO) (APHQF) has significant investments in the United States legal marijuana market (Florida and Arizona). In October, the Canadian licensed medical marijuana producer expanded its reach outside of North America and completed its first shipment of cannabis oil to Medlab Clinical Limited (MDC: ASX), an Australian medical life science company. We are favorable on this relationship and on Aphria’s exposure to the Australian medical marijuana market. We will keep an eye on how Aphria continues to execute and if it chooses to target new international markets after this development.
4. Over the last quarter, Cronos Group (MJN.V) (PRMCF) has focused on expanding its reach and entering new legal cannabis markets. Last month, Cronos signed a five-year exclusive distribution partnership with G. Pohl-Boskamp GmbH & Co, which distributes its products to over 12,000 pharmacies in Germany. Last month, Cronos signed a joint venture partnership with an Israeli company for the production, manufacture and global distribution of medical cannabis. In late August, Cronos exported its first shipment of medical cannabis oil to the Cayman Islands. We are favorable on Cronos’ continued execution and long-term outlook.
5. CanniMed Therapeutics (CMED.TO)(CMMDF) has benefited from its leverage to two emerging trends in the legal cannabis industry, the international opportunities and the demand for smokeless cannabis products. Earlier this year, CanniMed completed its first shipment of commercial cannabis oil to Australia and the Cayman Islands. CanniMed continues to focus on new market opportunities and in late August, the company signed a definitive supply agreement with a private South African corporation.
6. Maricann Group (MARI.CN) (MRRCF) has been one of the top performing licensed producers over the last month and we are favorable on the company’s leverage to the Canadian and German medical marijuana market. We consider Maricann to be an acquisition target and view the company as an attractive opportunity for any licensed producer trying to expand their presence. Maricann has an attractive valuation and we are favorable on the company’s long-term outlook.
7. Last month, ICC International Cannabis (ICC.V) (ICCLF) entered a presales agreement with Grupo Fénix for its proprietary line of CBD oil. Grupo Fénix is a large Mexican company that manages hundreds of pharmacies. ICC continues to expand and has been in discussions with several government and healthcare agencies in South America. While we do not rank ICC near the top of the best Canadian companies, we are favorable on these recent developments, the company’s valuation, and it’s opportunities in South America.